Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

mRNA 4157

Drug Profile

mRNA 4157

Alternative Names: mRNA-4157; mRNA-4157/V940; PCV; Personalized Cancer Vaccine - Moderna Therapeutics

Latest Information Update: 15 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Moderna Therapeutics
  • Developer Merck Sharp & Dohme; Moderna Therapeutics
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; RNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Malignant melanoma; Non-small cell lung cancer
  • Phase I Solid tumours

Most Recent Events

  • 12 Mar 2024 Merck Sharp & Dohme and Moderna plan a phase II trial for Bladder cancer (Adjuvant therapy, Combination therapy, First-line therapy) (IM, Injection) in April 2024 (NCT06305767) (EudraCT2023-505658-17)
  • 12 Mar 2024 Merck Sharp & Dohme in collaboration with ModernaTX plans a phase II V940-004 trial in Renal cell carcinoma (Adjuvant therapy, Combination therapy) (IM) in April 2024 (NCT06307431) (EudraCT2023-505177-32)
  • 29 Feb 2024 Merck in collaboration with Moderna plans a phase II/III INTerpath-007 for Squamous cell cancer (Late-stage disease, Combination therapy, Neoadjuvant therapy) (IV) in April 2024 (NCT06295809) (EudraCT2023-505712-37)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top